Progress against solid tumors in danger

The metastatic breast cancer example

Javier Corteś, Emiliano Calvo, Antonio González-Martín, Shaheenah Dawood, Antonio Llombart-Cussac, Leticia De Mattos-Arruda, Patricia Gómez, Orlando Silva, Edith A. Perez, Hope S. Rugo, Ana Lluch, Gabriel N. Hortobagyi

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The high prices of drugs and the worldwide economic and financial crisis are concerning. Of course, additional research might elucidate the subgroup of patients who will experience greater benefit, but as scientists and physicians, we should clearly separate value and price. Asurvey to assess the perception of health care workers involved in the management of women with MBC on the FDA's decision to ascertain how it will affect practice and to determine how bevacizumab is commonly used in the community for MBC was conducted. These survey results highlight the discord between the opinion of community oncologists and the FDA's recent decision to withdraw the indication of bevacizumab for MBC.33 Apositive trial is based on a statistically significant P value, which should not be confused with clinical meaning. In addition, the concept of clinicalmeaningis closely related with costs. IfOSis the primaryend point of first-line trials, only the prognosis of a few tumors will be improved, and only over the course of a few years. This controversy is not only relevant to bevacizumab in MBC. The lack of consistency and transparency in the drug approval process is dangerous and likely to discourage pharmaceutical companies from developing new drugs. Progress in our fight to cure cancer will be jeopardized if we confuse value and price.

Original languageEnglish (US)
Pages (from-to)3444-3447
Number of pages4
JournalJournal of Clinical Oncology
Volume30
Issue number28
DOIs
StatePublished - Oct 1 2012

Fingerprint

Breast Neoplasms
Pharmaceutical Preparations
Drug Approval
Neoplasms
Economics
Delivery of Health Care
Physicians
Costs and Cost Analysis
Research
Bevacizumab
Surveys and Questionnaires
Oncologists

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Corteś, J., Calvo, E., González-Martín, A., Dawood, S., Llombart-Cussac, A., De Mattos-Arruda, L., ... Hortobagyi, G. N. (2012). Progress against solid tumors in danger: The metastatic breast cancer example. Journal of Clinical Oncology, 30(28), 3444-3447. https://doi.org/10.1200/JCO.2012.41.9580

Progress against solid tumors in danger : The metastatic breast cancer example. / Corteś, Javier; Calvo, Emiliano; González-Martín, Antonio; Dawood, Shaheenah; Llombart-Cussac, Antonio; De Mattos-Arruda, Leticia; Gómez, Patricia; Silva, Orlando; Perez, Edith A.; Rugo, Hope S.; Lluch, Ana; Hortobagyi, Gabriel N.

In: Journal of Clinical Oncology, Vol. 30, No. 28, 01.10.2012, p. 3444-3447.

Research output: Contribution to journalArticle

Corteś, J, Calvo, E, González-Martín, A, Dawood, S, Llombart-Cussac, A, De Mattos-Arruda, L, Gómez, P, Silva, O, Perez, EA, Rugo, HS, Lluch, A & Hortobagyi, GN 2012, 'Progress against solid tumors in danger: The metastatic breast cancer example', Journal of Clinical Oncology, vol. 30, no. 28, pp. 3444-3447. https://doi.org/10.1200/JCO.2012.41.9580
Corteś J, Calvo E, González-Martín A, Dawood S, Llombart-Cussac A, De Mattos-Arruda L et al. Progress against solid tumors in danger: The metastatic breast cancer example. Journal of Clinical Oncology. 2012 Oct 1;30(28):3444-3447. https://doi.org/10.1200/JCO.2012.41.9580
Corteś, Javier ; Calvo, Emiliano ; González-Martín, Antonio ; Dawood, Shaheenah ; Llombart-Cussac, Antonio ; De Mattos-Arruda, Leticia ; Gómez, Patricia ; Silva, Orlando ; Perez, Edith A. ; Rugo, Hope S. ; Lluch, Ana ; Hortobagyi, Gabriel N. / Progress against solid tumors in danger : The metastatic breast cancer example. In: Journal of Clinical Oncology. 2012 ; Vol. 30, No. 28. pp. 3444-3447.
@article{c27581ab9e524e4881a1179fd917cb32,
title = "Progress against solid tumors in danger: The metastatic breast cancer example",
abstract = "The high prices of drugs and the worldwide economic and financial crisis are concerning. Of course, additional research might elucidate the subgroup of patients who will experience greater benefit, but as scientists and physicians, we should clearly separate value and price. Asurvey to assess the perception of health care workers involved in the management of women with MBC on the FDA's decision to ascertain how it will affect practice and to determine how bevacizumab is commonly used in the community for MBC was conducted. These survey results highlight the discord between the opinion of community oncologists and the FDA's recent decision to withdraw the indication of bevacizumab for MBC.33 Apositive trial is based on a statistically significant P value, which should not be confused with clinical meaning. In addition, the concept of clinicalmeaningis closely related with costs. IfOSis the primaryend point of first-line trials, only the prognosis of a few tumors will be improved, and only over the course of a few years. This controversy is not only relevant to bevacizumab in MBC. The lack of consistency and transparency in the drug approval process is dangerous and likely to discourage pharmaceutical companies from developing new drugs. Progress in our fight to cure cancer will be jeopardized if we confuse value and price.",
author = "Javier Corteś and Emiliano Calvo and Antonio Gonz{\'a}lez-Mart{\'i}n and Shaheenah Dawood and Antonio Llombart-Cussac and {De Mattos-Arruda}, Leticia and Patricia G{\'o}mez and Orlando Silva and Perez, {Edith A.} and Rugo, {Hope S.} and Ana Lluch and Hortobagyi, {Gabriel N.}",
year = "2012",
month = "10",
day = "1",
doi = "10.1200/JCO.2012.41.9580",
language = "English (US)",
volume = "30",
pages = "3444--3447",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "28",

}

TY - JOUR

T1 - Progress against solid tumors in danger

T2 - The metastatic breast cancer example

AU - Corteś, Javier

AU - Calvo, Emiliano

AU - González-Martín, Antonio

AU - Dawood, Shaheenah

AU - Llombart-Cussac, Antonio

AU - De Mattos-Arruda, Leticia

AU - Gómez, Patricia

AU - Silva, Orlando

AU - Perez, Edith A.

AU - Rugo, Hope S.

AU - Lluch, Ana

AU - Hortobagyi, Gabriel N.

PY - 2012/10/1

Y1 - 2012/10/1

N2 - The high prices of drugs and the worldwide economic and financial crisis are concerning. Of course, additional research might elucidate the subgroup of patients who will experience greater benefit, but as scientists and physicians, we should clearly separate value and price. Asurvey to assess the perception of health care workers involved in the management of women with MBC on the FDA's decision to ascertain how it will affect practice and to determine how bevacizumab is commonly used in the community for MBC was conducted. These survey results highlight the discord between the opinion of community oncologists and the FDA's recent decision to withdraw the indication of bevacizumab for MBC.33 Apositive trial is based on a statistically significant P value, which should not be confused with clinical meaning. In addition, the concept of clinicalmeaningis closely related with costs. IfOSis the primaryend point of first-line trials, only the prognosis of a few tumors will be improved, and only over the course of a few years. This controversy is not only relevant to bevacizumab in MBC. The lack of consistency and transparency in the drug approval process is dangerous and likely to discourage pharmaceutical companies from developing new drugs. Progress in our fight to cure cancer will be jeopardized if we confuse value and price.

AB - The high prices of drugs and the worldwide economic and financial crisis are concerning. Of course, additional research might elucidate the subgroup of patients who will experience greater benefit, but as scientists and physicians, we should clearly separate value and price. Asurvey to assess the perception of health care workers involved in the management of women with MBC on the FDA's decision to ascertain how it will affect practice and to determine how bevacizumab is commonly used in the community for MBC was conducted. These survey results highlight the discord between the opinion of community oncologists and the FDA's recent decision to withdraw the indication of bevacizumab for MBC.33 Apositive trial is based on a statistically significant P value, which should not be confused with clinical meaning. In addition, the concept of clinicalmeaningis closely related with costs. IfOSis the primaryend point of first-line trials, only the prognosis of a few tumors will be improved, and only over the course of a few years. This controversy is not only relevant to bevacizumab in MBC. The lack of consistency and transparency in the drug approval process is dangerous and likely to discourage pharmaceutical companies from developing new drugs. Progress in our fight to cure cancer will be jeopardized if we confuse value and price.

UR - http://www.scopus.com/inward/record.url?scp=84867042331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867042331&partnerID=8YFLogxK

U2 - 10.1200/JCO.2012.41.9580

DO - 10.1200/JCO.2012.41.9580

M3 - Article

VL - 30

SP - 3444

EP - 3447

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 28

ER -